Owen Mumford
| Owen Mumford | |
|---|---|
| legal form | Ltd. |
| founding | 1952 |
| Seat | Woodstock , UK |
| management | Mark Owen |
| Number of employees | 600 |
| Branch | Medical device manufacturer, medical technology |
| Website | www.owenmumford.com |
Owen Mumford Ltd. is an international family company based in Woodstock , Great Britain, that manufactures, develops, markets and sells small medical devices.
history
In 1952, Ivan Owen and John Mumford founded the company for the manufacture of medical technology devices in a small garage owned by Ivan's father, Tom Owen. Their first product was an improved version of the Macintosh laryngoscope . In 1958, a former glove factory on Oxford Street in Woodstock was bought and expanded into the new company headquarters. This was followed by the Oxford inflation bellows, the Radcliffe humidifier and other anesthetic accessories. The manufacture of aluminum molds for the domestic plastic injection industry was also part of the precision technology division. Owen Mumford was thus also an important supplier of molds for the British automotive industry.
In March 1978 the product "Autolet", the world's first automatic lancing device, was introduced, with which diabetics could draw capillary blood themselves. This led to an enormous demand for sterile lancets . In 1982 the company entered the medical consumables market and manufactured sterile lancets under the “Unilet” brand. At the end of the 1990s, the “Accupen”, the world's first insulin pen, was produced. In the 1990s, sales continued to rise, and OEM contracts were signed with internationally active pharmaceutical and diagnostic manufacturers with the new follow-up products “Autopen” (insulin dosing system) and the “Unistik 3” safety lancets . In 1992 the production of molds was discontinued and a new production facility was built in Chipping Norton, Oxfordshire, which was expanded again in May 2007.
In December 2009 the company signed a three-year supply agreement with Sanofi Aventis for the reusable "Autopen 24" insulin pens. The company's sales are estimated at between $ 100 million and $ 200 million. According to its competitor Ypsomed , Owen Mumford's global market share among diabetes device manufacturers is around 18 percent.
The company's current CEO is Mark Owen.
The branch in Germany is located in Großostheim- Ringheim. There are further branches in France, the USA, Mexico, Malaysia and the People's Republic of China.
Products
Products include insulin pens, pen needles, safety lancets, lancets, neuropathy screening devices, and sexual health products such as vaginal dilators and vacuum erectors.